|
(11) Diet Modification to Augment Radiation for Breast Cancer Brain Metastases
|
1R01CA227479-01
|
$351,726
|
|
SIMONE, NICOLE
|
THOMAS JEFFERSON UNIVERSITY
|
|
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
|
1R01CA227466-01
|
$699,062
|
|
ZIV, ELAD
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
|
1R01CA227505-01
|
$620,860
|
|
KIRCHHOFF, TOMAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ1) Characterization of Premalignant Fields in a Murine Model of Head and Neck and Esophageal Cancers
|
5R01CA205258-03
|
$464,261
|
|
GUDAS, LORRAINE
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
(PQ1) Epigenetic effects of the premalignant field
|
5R01CA208620-03
|
$415,599
|
|
TERADA, LANCE
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
(PQ1) Progression of the airway field of injury to Kras mutant lung cancer
|
5R01CA205608-03
|
$346,909
|
|
SCHEET, PAUL
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
|
1R01CA219896-01A1
|
$429,943
|
|
WARGO, JENNIFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes
|
1R21CA227232-01
|
$208,746
|
|
TURNBAUGH, PETER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ10) Understanding How Commensal Microbiota Affect the Anti-tumor Action of Radiotherapy
|
1R21CA227528-01
|
$176,175
|
|
WEICHSELBAUM, RALPH
|
UNIVERSITY OF CHICAGO
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-03
|
$706,386
|
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-03
|
$518,165
|
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years
|
5R01CA206477-03
|
$791,933
|
|
PALEFSKY, JOEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(PQ5) Relevance of VDAC2 heterogeneity for hepatic tumor growth and targeting
|
1R01CA216254-01A1
|
$413,916
|
|
HAJNOCZKY, GYORGY
|
THOMAS JEFFERSON UNIVERSITY
|
|
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
|
5R01CA205101-03
|
$384,612
|
|
SKALA, MELISSA
|
MORGRIDGE INSTITUTE FOR RESEARCH, INC.
|
|
(PQA2) Impact of obesity on endogenous mutational hotspots
|
1R21CA185508-01
|
$201,623
|
$201,623
|
VASQUEZ, KAREN
|
UNIVERSITY OF TEXAS, AUSTIN
|
|
(PQC3) Ethnicity-determined immune response and DCIS outcome
|
5R01CA194600-04
|
$179,518
|
|
BADVE, SUNIL
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
(PQD1) Treatment-emergent resistance to NEDD8-activating enzyme inhibition
|
3R01CA180150-02S1
|
$108,952
|
$108,952
|
PETROSKI, MATTHEW
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
(PQD1) Treatment-emergent resistance to NEDD8-activating enzyme inhibition
|
5R01CA180150-02
|
$541,578
|
$541,578
|
PETROSKI, MATTHEW
|
SANFORD-BURNHAM MEDICAL RESEARCH INSTIT
|
|
(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
|
5R21CA180097-02
|
$192,409
|
$192,409
|
DITTMER, DIRK
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies
|
1R01CA185372-01
|
$329,519
|
$329,519
|
RICHARDS, KRISTY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
(PQD5)Biomaterials-based Adaptive Tumor Microenvironments for In Vitro Drug Scree
|
1R21CA185236-01
|
$179,619
|
$179,619
|
SINGH, ANKUR
|
CORNELL UNIVERSITY
|
|
00000000; D.GUY; SEVERABLE OPERATIONS FOR NCI-FREDERICK
|
261200800001E
|
$296,673,020
|
$603,009
|
Heimbrook, David
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer
|
5R01CA201250-03
|
$695,342
|
|
LARSON, STEVEN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
A bifunctional nanomedicine for both specific imaging and targeting therapy of an
|
5R01CA151955-05
|
$300,665
|
$300,665
|
ZU, YOULI
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
|
A blood test to identify prostate cancer patients at risk for visceral metastasis
|
5R01CA218356-02
|
$601,750
|
|
POSADAS, EDWIN
|
CEDARS-SINAI MEDICAL CENTER
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120 - 02060
|
$286,453
|
$57,291
|
Rothman, Nathaniel
|
DCEG (NCI)
|
|
A Fourth Outcome: DNA Damage and the Differentiation of B Cells
|
5R01CA156674-04
|
$305,437
|
$305,437
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
A genomewide discovery of chemoresistance-associated noncoding RNAs in human cancers
|
1R21CA226303-01
|
$176,175
|
|
HE, TONG-CHUAN
|
UNIVERSITY OF CHICAGO
|
|
A high efficiency imager for real-time lung cancer monitoring during radiotherapy
|
5R01CA188446-05
|
$765,486
|
|
BERBECO, ROSS
|
DANA-FARBER CANCER INST
|
|
A Modifier of Plasmacytoma Susceptibility Maps to Mouse Chr 1
|
ZIA BC 011064
|
$109,375
|
$21,875
|
Mock, Beverly
|
CCR (NCI)
|
|
A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph)
|
ZIA CP010136 - 10512
|
$1,457,188
|
$1,457,188
|
Lan, Qing
|
DCEG (NCI)
|
|
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
|
5U01CA199252-04
|
$1,041,188
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A MULTILEVEL APPROACH TO ENERGY BALANCE AND CANCER ACROSS THE LIFECOURSE
|
5U54CA155496-04
|
$1,660,228
|
$448,262
|
COLDITZ, GRAHAM
|
WASHINGTON UNIVERSITY
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
3R01CA190776-04S1
|
$116,456
|
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5R01CA166894-06
|
$368,984
|
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma
|
2R44CA159843-02
|
$748,921
|
$748,921
|
BALHORN, RODNEY
|
SHAL TECHNOLOGIES, INC.
|
|
A new technology to isolate RNP complexes of a polycistronic miRNA oncogene
|
5R21CA175560-02
|
$194,176
|
$194,176
|
HE, LIN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
A New Treatment Paradigm for ALK-Driven Cancers Exploiting Oncogene Overdose
|
1R01CA190696-01
|
$316,610
|
$316,610
|
SCHATZ, JONATHAN
|
UNIVERSITY OF ARIZONA
|
|
A Novel Druggable Epigenetic Vulnerability Pathway in HCC
|
1R01CA218008-01A1
|
$599,752
|
|
GREEN, MICHAEL
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
A Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain Tumors
|
5R01CA217956-02
|
$688,403
|
|
BRADY-KALNAY, SUSANN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Novel Multimodality Immune Based Platform in Advanced Mycosis Fungoides
|
1R03CA184127-01
|
$84,750
|
$84,750
|
DIEFENBACH, CATHERINE
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
A novel NKG2D-specific BiTE cancer immunotherapy
|
5R01CA164178-02
|
$326,066
|
$163,033
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
|
A Pathway of Tumor Suppression
|
5R01CA047296-26
|
$242,092
|
$79,890
|
LOZANO, GUILLERMINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
A Phase I trial combining IV fenretinide and IV safingol to target overproduction
|
1R44CA183316-01
|
$190,601
|
$190,601
|
SIMPSON, WILLIAM
|
CERRX, INC.
|
|
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
|
5R01CA149445-04
|
$577,153
|
$577,153
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A Prospective Investigation of the Oral Microbiome and Pancreatic Cancer
|
5U01CA187508-04
|
$430,565
|
|
PALMER, JULIE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A Prospective, Randomized Study to Compare Effects of Ulipristal Acetate with a Combined Oral Contraceptive on Breast Epithelial Cell Proliferation.
|
5R01CA200795-03
|
$406,451
|
|
WESTHOFF, CAROLYN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
A Psychosocial Intervention to Improve Outcomes for Parents with Advanced Cancer
|
5K07CA218167-02
|
$176,839
|
|
PARK, ELIZA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
A Randomized Controlled Trial of an HPV Vaccine Intervention for Young Sexual Minority Men
|
1R37CA226682-01
|
$602,822
|
|
REITER, PAUL
|
OHIO STATE UNIVERSITY
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$225,712
|
$22,571
|
Tosato, Giovanna
|
CCR (NCI)
|
Total relevant funding to Non Hodgkins Lymphoma for this search: $122,382,257
|